0001740797-26-000009
SEC filingAvant Technologies Inc. reported a net loss of $554K for Q3 2026, with no revenue disclosed for the period. The company incurred total operating expenses of $510K, primarily driven by laboratory services ($185K), general and administrative expenses ($190K), and consulting services ($60K). The balance sheet shows total assets of $173K against total liabilities of $3.0M, resulting in a stockholders' deficit of $2.8M, indicating significant financial leverage. Cash flow from operations was negative $959K, partially offset by $928K in financing activities, leading to a net cash decrease of $31K for the quarter. The company's liquidity position remains constrained with cash and equivalents of $50K at period end.
Avant Technologies Inc. reported a net loss of $554K for Q3 2026 ending December 31, 2025, with no revenue disclosed for the period. The company's operating loss was $554K, driven by total operating expenses of $510K and other expenses of $44K. Key expense components included laboratory services ($185K), general and administrative expenses ($190K), consulting services ($60K), marketing expenses ($55K), research and development ($24K), professional fees ($13K), website expenses ($11K), amortization expense ($7K), and rent expenses ($857). The company reported net loss per share of $0 for both basic and diluted calculations, with weighted average shares outstanding of 138.0 million.
No revenue data was disclosed in the filing for Q3 2026. The income statement shows revenue as not available (N/A), indicating the company may not have generated significant revenue during the period. The document does not provide segment breakdowns, geographic mix, or revenue growth drivers. All financial performance metrics relate to expense management and loss containment rather than revenue generation.
The company reported negative profitability metrics with a net loss of $554K for the quarter. Operating margin cannot be calculated due to the absence of revenue data. The cost structure shows operating expenses dominated by laboratory services ($185K) and general and administrative expenses ($190K), which together represent approximately 73% of total operating expenses. Other significant costs include consulting services ($60K), marketing expenses ($55K), and research and development ($24K). The company's expense profile suggests ongoing operational and development activities despite the absence of reported revenue.
Cash flow from operating activities was negative $959K, primarily driven by a net loss of $1.5M, partially offset by increases in accounts payable ($514K) and amortization ($20K). Financing activities provided $928K in cash, mainly from loan payable ($550K), loan from related parties ($186K), and additional paid-in capital ($263K). The net cash decrease for the period was $31K, with ending cash of $81K. The balance sheet shows total assets of $173K, including cash and equivalents ($50K), prepaid expenses ($10K), and intangible assets ($112K). Total liabilities of $3.0M consist primarily of accounts payable ($1.4M), loan from related parties ($698K), loan payable ($550K), and convertible notes payable ($320K). Stockholders' deficit stands at $2.8M with accumulated deficit of $5.6M.
The filing does not contain specific forward-looking statements, management guidance, or strategic priorities. No risk factors or future outlook commentary is provided in the document content. The financial data suggests the company continues to operate at a loss with negative cash flow from operations, relying on financing activities to maintain liquidity. The balance sheet indicates significant leverage with liabilities substantially exceeding assets, resulting in a material stockholders' deficit position.